- Differential Diagnosis
Drug Information for FENTORA CII (fentanyl buccal tablet) (Cephalon, Inc.): INDICATIONS AND USAGE
- INDICATIONS AND USAGE
- DOSAGE AND ADMINISTRATION
- SAFETY AND HANDLING
- DISPOSAL OF FENTORA
- HOW SUPPLIED
- Medication Guide
- Diseases/Conditions Related to FENTORA CII (fentanyl buccal tablet) (Cephalon, Inc.)
- External Links Related to FENTORA CII (fentanyl buccal tablet) (Cephalon, Inc.)
(See BOXED WARNING andCONTRAINDICATIONS)
FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation could occur at any dose in patients not on a chronic regimen of opiates. For this reason, FENTORA is contraindicated in the management of acute or postoperative pain.
FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.
- Drug Information Provided by National Library of Medicine (NLM).